Liposomal borrelidin for treatment of metastatic breast cancer

Area of Science:

• Pharmacology
• Oncology
• Nanotechnology

Background:

• Borrelidin, an inhibitor of threonyl-tRNA synthetase, exhibits anticancer and antiangiogenic properties.
• Severe liver toxicity limits the clinical application of borrelidin for metastatic cancer treatment.
• Developing targeted drug delivery systems can mitigate toxicity and enhance therapeutic efficacy.

Purpose of the Study:

• To develop and optimize a liposomal formulation of borrelidin for metastatic breast cancer treatment.
• To evaluate the efficacy of liposomal borrelidin in inhibiting tumor growth and metastasis.
• To assess the safety profile of liposomal borrelidin, focusing on liver toxicity.

Main Methods:

• Liposomal formulation of borrelidin was developed and optimized for stability and drug loading.
• In vitro studies assessed the effects of liposomal borrelidin on tumor cell proliferation, migration, and endothelial cell angiogenesis.
• In vivo studies in a mouse model of metastatic breast cancer evaluated tumor growth inhibition, metastasis reduction, and systemic toxicity.

Main Results:

• Liposomal borrelidin demonstrated significant in vitro anticancer and antiangiogenic activities.
• Liposomal borrelidin showed superior inhibition of primary tumor growth and lung metastasis compared to free borrelidin in vivo.
• Multiple injections of liposomal borrelidin did not induce significant systemic toxicity in the mouse model.

Conclusions:

• Liposomal formulation is a promising strategy to enhance the therapeutic potential of borrelidin for metastatic breast cancer.
• Liposomal borrelidin effectively targets primary tumors and reduces metastasis while minimizing liver toxicity.
• This approach offers a safer and more effective treatment option for metastatic breast cancer.